Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: A nested case-control study

Lancet

Volumn 355, Issue 9222, 2000, Pages 2194-2198

  Ylitalo, Nathalie ^a   Sørensen, Per ^b   Josefsson, Agnetha M ^c   Magnusson, Patrik K E ^c   Kragh Andersen, Per ^b,d   Pontén, Jan ^c   Adami, Hans Olov ^a,e   Gyllensten, Ulf B ^c   Melbye, Mads ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b S   (Denmark)

^c UPPSALA UNIVERSITY   (Sweden)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; CANCER RISK; CANCER SCREENING; CASE CONTROL STUDY; CONTROLLED STUDY; CYTOLOGY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SWEDEN; UTERINE CERVIX CARCINOMA IN SITU; VIRUS LOAD; WART VIRUS;

EID: 0034709690     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02402-8     Document Type: Article

References (28)

1. Cuzick J. Viral load as a surrogate for persistence in cervical human papillomavirus infection. Franco E., Monsonego J. New developments in cervical cancer screening and prevention. 1997;373-378 Blackwell Science, Oxford.
2. Terry G., Ho L., Jenkins D.et al. Definition of human papillomavirus type 16 DNA levels in low and high grade cervical lesions by a simple polymerase chain reaction technique. Arch Virol. 128:1993;123-133.
3. Brisson J., Bairati I., Morin C.et al. Determinants of persistent detection of human papillomavirus DNA in the uterine cervix. J Infect Dis. 173:1996;794-799.
4. Cuzick J., Terry G., Hollingworth T., Anderson M. Human papillomavirus type 16 DNA in cervical smears as predictors of high-grade cervical intraepithelial neoplasia. Lancet. 339:1992;959-960.
5. Cuzick J., Terry G., Ho L., Hollingworth T., Anderson M. Type-specific human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia. Br J Cancer. 69:1994;167-171.
6. Ho G.Y.F., Kadish A.S., Burk R.D.et al. HPV 16 and cigarette smoking as risk factors for high-grade cervical intra-epithelial neoplasia. Int J Cancer. 78:1998;281-285.
7. Ho G.Y.F., Palan P.R., Basu J.et al. Viral characteristics of human papillomavirus infection and antioxidant levels as risk factors for cervical dysplasia. Int J Cancer. 78:1998;594-599.
8. Gustafsson L., Sparén P., Gustafsson M., Wilander E., Bergström R., Adami H.-O. Efficiency of organised and opportunistic cytological screening for cancer in situ of the cervix. Br J Cancer. 72:1995;498-505.
9. Ylitalo N., Sørensen P., Josefsson A.et al. Smoking and oral contraceptives as risk factors for cervical carcinoma in situ. Int J Cancer. 81:1999;357-365.
10. Chua K.L., Hjerpe A. Polymerase chain reaction analysis of human papillomavirus in archival cytologic smears. Anal Quant Cytol Histol. 17:1995;221-229.
11. Josefsson A., Livak K., Gyllensten U. Detection and quantitation of human papillomavirus by using the fluorescent 5′ exonuclease assay. J Clin Microbiol. 37:1999;490-496.
12. Holland P.M., Abrahamson R.D., Watson R., Gelfand D.H. Detection of specific polymerase chain reaction product by utilizing the 5′-3′exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci (USA). 88:1991;7276-7280.
13. Heid C.A., Stevens J., Livak K.J., Williams P.M. Real time quantitative PCR. Genome Res. 6:1996;986-994.
14. Lee L.G., Connell C.R., Bloch W. Allelic discrimination by nick-translation PCR with fluorogenic probes. Nucleic Acids Res. 21:1993;3761-3766.
15. Ylitalo N., Bergström T., Gyllensten U. Detection of genital human papillomavirus by single-tube nested PCR and type-specific oligonucleotide hybridization. J Clin Microbiol. 33:1995;1822-1828.
16. Josefsson A.M., Magnusson P.K.E., Ylitalo N.et al. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ. Lancet. 355:2000;2189-2193.
17. Borgan Ø., Langholz B. Estimation of absolute risk from nested case-control data. Biometrics. 53:1997;767-774.
18. Swan D.C., Tucker R.A., Tortolero-Luna G.et al. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. J Clin Microbiol. 37:1999;1030-1034.
19. Bosch F.X., Manos M.M., Munoz N.et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst. 87:1995;796-802.
20. Pontén J., Adami H.-O., Bergström R.et al. Strategies for global control of cervical cancer. Int J Cancer. 60:1995;1-26.
21. Munoz N., Bosch F.X. Current views on the epidemiology of HPV and cervical cancer. Lacey C. Papillomavirus reviews: current research on papillomaviruses. 1996;227-237 Leeds University Press, Leeds.
22. Sun X.-W., Kuhn L., Ellerbrock T.V., Chiasson M.A., Bush T.J., Wright T.C. Jr. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med. 337:1997;1343-1349.
23. Maiman M. Management of cervical neoplasia in human immunodeficiency virus-infected women. J Natl Cancer Inst Monogr. 23:1998;43-49.
24. Palefsky J. Human papillomavirus infection among HIV-infected individuals. implications for development of malignant tumors Hematol Oncol Clin North Am. 5:1991;357-370.
25. Quinn M., Babb P., Jones J., Allen E. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ. 318:1999;904-908.
26. Sasieni P., Cuzick J., Farmery E. Accelerated decline in cervical cancer mortality in England and Wales. Lancet. 346:1995;1566-1567.
27. Cuzick J., Sasieni P. Estimates of the cost impact of introducing human papillomavirus testing into cervical screening programme. Franco E., Monsonego J. New developments in cervical cancer screening and prevention. 1997;364-372 Blackwell Science, Oxford.
28. Manos M.M., Kinney W.K., Hurley L.B.et al. Identifying women with cervical neoplasia using human papillomavirus DNA testing for equivocal papanicolaou results. JAMA. 281:1999;1605-1610.